The government's scrutiny of Gilead's pricing of its Hep C drug appears to be one of the catalysts of the bio-tech sell off. According to a report in the NY Times, a six month treatment of the drug in the US will cost $168,000. It is estimated that the same treatment will cost $2,000 in India. The rest of the world will have prices somewhere between those of India and the US. Although the sell off has cost me some money, it is understandable that the government question why our patients, Medicare, and insurance companies have to pay the highest prices. Recently I have talked to people who take vacations to other countries just to have medical work done. A niece of mine takes a yearly vacation to Israel to visit family and have any needed dental work done. She says that the money she saves on dental insurance and treatment cost practically pays for her vacation.